In the striatum, presynaptic α6-containing nicotinic receptors are crucially involved in the modulation of dopamine release. CVN417, a novel selective antagonist at this receptor subtype, attenuates motor dysfunction in a Parkinson’s disease-relevant animal model, suggesting, for this pathology, a therapeutic strategy that could greatly profit from the restricted localization of α6* nicotinic receptors in the brain.
Addressing Motor Dysfunction by a Selective α6-Containing Nicotinic Receptor Antagonist / C. Bolchi, M. Pallavicini. - In: JOURNAL OF MEDICINAL CHEMISTRY. - ISSN 1520-4804. - 66:21(2023 Nov), pp. 14494-14496. [10.1021/acs.jmedchem.3c01817]
Addressing Motor Dysfunction by a Selective α6-Containing Nicotinic Receptor Antagonist
C. Bolchi
Primo
;M. PallaviciniUltimo
2023
Abstract
In the striatum, presynaptic α6-containing nicotinic receptors are crucially involved in the modulation of dopamine release. CVN417, a novel selective antagonist at this receptor subtype, attenuates motor dysfunction in a Parkinson’s disease-relevant animal model, suggesting, for this pathology, a therapeutic strategy that could greatly profit from the restricted localization of α6* nicotinic receptors in the brain.File | Dimensione | Formato | |
---|---|---|---|
bolchi-pallavicini-2023-addressing-motor-dysfunction-by-a-selective-α6-containing-nicotinic-receptor-antagonist.pdf
accesso aperto
Tipologia:
Publisher's version/PDF
Dimensione
1.33 MB
Formato
Adobe PDF
|
1.33 MB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.